Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial
Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 889-892
DOI: 10.1093/cid/ciae514 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.11.2024. Verfasst von Loice Achieng Ombajo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya. Hauptthemen laut MEDLINE: Blood Pressure, Body Weight, Cardiovascular Diseases, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare, University of Nairobi, Ministry of Health Kenya.
Abstract (Originalsprache)
Among 777 virally suppressed adults with human immunodeficiency virus on protease-inhibitor–based second-line antiretroviral regimens randomized 1:1 to switch to dolutegravir or remain on a protease inhibitor, there was no difference in incident hypertension (12% in each arm, P = .868) or change in blood pressure over the 48-week study period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya.
- Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya.
- Department of Family Practice, University of British Columbia, Vancouver, Canada.
- Department of Medicine, Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya.
- Comprehensive Care Center, Kenyatta National Hospital, Nairobi, Kenya.
- Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.
ORCID-Profile: Loice Achieng Ombajo, Jeremy Penner, Joseph Nkuranga, Anton Pozniak
Förderung
- ViiV Healthcare
- University of Nairobi
- Ministry of Health Kenya
Zitieren
APA
Ombajo, L. A., Penner, J., Nkuranga, J., Omodi, V., Otieno, E., Ndinya, F., Wahome, S., & Pozniak, A. (2025). Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. Clinical Infectious Diseases, 80(4), 889-892. https://doi.org/10.1093/cid/ciae514
Vancouver
Ombajo LA, Penner J, Nkuranga J, Omodi V, Otieno E, Ndinya F, et al. Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. Clinical Infectious Diseases. 2025;80(4):889-892. doi:10.1093/cid/ciae514
BibTeX
@article{Ombajo2025,
author = {Ombajo, Loice Achieng and Penner, Jeremy and Nkuranga, Joseph and Omodi, Victor and Otieno, Edwin and Ndinya, Florentius and Wahome, Simon and Pozniak, Anton},
title = {Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {4},
pages = {889--892},
doi = {10.1093/cid/ciae514}
}
EUVIMED